Loading...
Loading...
DICE| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 21.7M |
| Operating I/L | -21.7M |
| Other Income/Expense | 0.2M |
| Interest Income | 0.5M |
| Pretax | -21.5M |
| Income Tax Expense | 0.2M |
| Net Income/Loss | -21.7M |
DICE Therapeutics, Inc. is a biopharmaceutical company specializing in developing oral therapeutic candidates for chronic diseases in immunology and other therapeutic areas. The company's platform, DELSCAPE, is focused on discovering selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. Their lead therapeutic candidate, DC-806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, with potential applications in various immunology indications. Additionally, DICE Therapeutics is developing oral therapeutic candidates targeting a4ß7 integrin for inflammatory bowel diseases and aVß1/aVß6 integrin for idiopathic pulmonary fibrosis treatment, while also focusing on immuno-oncology for antibody therapeutics.
